Live Breaking News & Updates on While Bharat Biotech
Stay updated with breaking news from While bharat biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Covaxin, India’s homegrown Covid-19 vaccine, has shown 78 per cent protective efficacy against symptomatic infection and 93 per cent efficacy against severe disease, the vaccine’s developers said on Saturday making public clinical trial results. Covaxin also shows 65 per cent efficacy against the highly-transmissible Delta variant of the coronavirus, the vaccine maker Bharat Biotech and the Indian Council of Medical Research (ICMR) said in a paper that is not peer-reviewed yet but posted online on a preprint server. Advertisement While Bharat Biotech and the ICMR had announced efficacy results earlier this year, this is the first time they have released details of the trial on over 25,000 volunteers in hospitals across the country. ....
Indiaâs top court criticizes Narendra Modiâs government for a sluggish vaccination program. A line at a drive-in vaccination center in Ahmedabad, India, on Friday.Credit.Ajit Solanki/Associated Press June 3, 2021Updated 2:49 p.m. ET As Indiaâs Covid-19 vaccination drive falters, the countryâs Supreme Court has demanded that Prime Minister Narendra Modiâs government explain how it plans to meet its target of inoculating about 900 million adults by the end of the year. So far, India has administered about 220 million doses, and just 45 million people â about 4 percent of the population â are fully vaccinated with two doses. Vaccinating all adults would require at least another 1.5 billion doses. ....
The proposed study comes even as a study by English health officials said only two doses of Covishield provide strong protection against the B.1.617.2 variant of the coronavirus. ....
COVID-19 vaccination: Govt hopes to inoculate entire adult population by December The number of vaccines available in May would be 8.5 crore, 10 crore in June, 15 crore in July, 36 crore in August, 50 crore in September, 56 crore in October, 59 crore in November and 65 crore in December BusinessToday.In | May 15, 2021 | Updated 16:36 IST Explaining the availability of the Russian COVID-19 vaccine Sputnik V in the country, the sources added that around 60 lakh Sputnik V doses will be delivered in May The Centre has expressed optimism that a swift scale-up of COVID-19 vaccine availability from June should ensure that the current crunch, particularly for the 18-44 age group, ends by July. Following this, it will be feasible to vaccinate India s entire adult population of approx. 95 crore by this December, according to government sources. ....